Director/PDMR Shareholding

Venture Life Group PLC

30 September 2026

 

30 September 2026

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Company")

Director/PDMR Shareholding

Venture Life (AIM: VLG), a leader in product innovation, development and commercialisation within the global consumer healthcare sector, announces that Daniel Wells, Chief Financial Officer, has today purchased 38,717 ordinary shares of 0.3 pence each in the capital of the Company (“Ordinary Shares”) at a price of 64.548 pence per Ordinary Share.

Following the purchase, Mr Wells beneficially holds 38,717 Ordinary Shares representing approximately 0.03% per cent. of the Company's issued share capital.

For further information, please contact:

Venture Life Group PLC		[phone]
Jerry Randall, Chief Executive Officer Daniel Wells, Chief Financial Officer
Cavendish Capital Markets Limited (Nomad and Broker)		[phone]
Stephen Keys / George Lawson (Corporate Finance) Michael Johnson (Sales)

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, the Health & Her/Him product ranges supporting the hormonal lifecycle, FemiClear products addressing a range of common gynaecological conditions, plus the Curoxen brand providing infection prevention solutions for wounds and mouth sores.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK, Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

The Company makes the following disclosure in accordance with article 19(3) of the Market Abuse Regulation:

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Daniel Wells
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Venture Life Group plc
b)	LEI	213800S8CZUPLAB2KC70
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.3p each in Venture Life Group plc GB00BFPM8908
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price Volume 64.548 pence 38,717
d)	Aggregated information - Aggregated volume - Price	n/a
e)	Date of the transaction	30 September 2026
f)	Place of the transaction	London Stock Exchange

 

END